Procalcitonin in Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

Official title:

Role of Procalcitonin in Differantiation Between Bacerial Infection and Non Infectious Inflammation in Febrile Hepatocellular Carcinoma Patients After Locoregional Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01518829
• Other study ID #: HCC and Procalcitonin
• Status: Completed
• Phase: N/A
• First received: January 24, 2012
• Last updated: September 29, 2013
• Start date: April 2012
• Est. completion date: January 2013

Study information

• Verified date: September 2013
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Egypt: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: January 2013
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. - Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.

2. - Fever more than 38C after 48 hours post intervention.

Exclusion Criteria:

1. HCC Patients who does not develop fever after intervention.

2. Proven infection elsewhere (e.g. UTI, chest infection..)

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Locations

Country	Name	City	State
Egypt	Tropical medicine department and hepatocellular carcinoma clinic	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma		6months	Yes